IDXX:NSD-IDEXX Laboratories Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 413.62

Change

+0.46 (+0.11)%

Market Cap

USD 35.79B

Volume

0.16M

Analyst Target

USD 427.40
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
ILMN Illumina Inc

+0.22 (+0.16%)

USD 23.01B
NTRA Natera Inc

+0.40 (+0.25%)

USD 22.06B
ICLR ICON PLC

+3.24 (+1.54%)

USD 17.95B
EXAS EXACT Sciences Corporation

-0.82 (-1.39%)

USD 11.56B
MEDP Medpace Holdings Inc

+3.64 (+1.07%)

USD 10.75B
RDNT RadNet Inc

+0.74 (+1.02%)

USD 6.04B
GH Guardant Health Inc

+0.53 (+1.71%)

USD 3.91B
SHC Sotera Health Co

+0.22 (+1.65%)

USD 3.72B
VCYT Veracyte Inc

+0.19 (+0.46%)

USD 3.42B
TWST Twist Bioscience Corp

+0.78 (+1.62%)

USD 2.85B

ETFs Containing IDXX

PETZ:LSE 8.59 % 0.00 %

N/A

N/A
KATZ:XETRA 8.16 % 0.00 %

N/A

N/A
PETZ:SW 8.16 % 0.00 %

N/A

N/A
UMDV:SW iShares US Medical Device.. 3.57 % 0.00 %

N/A

N/A
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.43 (+0%)

N/A
JMIN 0.00 % 0.12 %

N/A

N/A
YXM.A:CA 0.00 % 1.49 %

N/A

N/A
YXM.D:CA 0.00 % 1.53 %

N/A

N/A
JUMF:XETRA 0.00 % 0.00 %

N/A

N/A
LCG Sterling Capital Focus Eq.. 0.00 % 0.00 %

+0.19 (+0%)

USD 0.04B
JUMF:F 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.48% 44% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.48% 44% F 29% F
Trailing 12 Months  
Capital Gain -25.61% 41% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.61% 41% F 29% F
Trailing 5 Years  
Capital Gain 58.21% 87% B+ 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.21% 87% B+ 74% C
Average Annual (5 Year Horizon)  
Capital Gain 15.85% 65% D 69% C-
Dividend Return 15.85% 65% D 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.94% 67% D+ 41% F
Risk Adjusted Return 34.49% 86% B+ 65% D
Market Capitalization 35.79B 100% F 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector